Accelerating Science and Technology

Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.

Read More

New collaborative clinical trial launches

Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP

Read More

Breakthrough Therapies In Action

Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.

Read More

Download the 2013 Annual Report

Friends of Cancer Research's 2013 Annual Report is now available for download.

Read More

Friends Hosts Breakthrough Briefing

Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing

Read More

Breakthrough Designations

View More

Dupilumab - (Regeneron and Sanofi)

for the treatment of atopic dermatitis


SPK-RPE65 - (Spark Therapeutics)

for the treatment of inherited retinal dystrophies (IRDs) caused by autosomal recessive mutations in the RPE65 gene


NBI-98854 - (Neurocrine Biosciences)

for the treatment of tardive dyskinesia


Recent Blogs

Leaders from advocacy, industry and government share their thoughts on the impact of Lung-MAP, a recently launched innovative clinical trial for lung cancer.


"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."

Ellen Sigal,
Chair, Friends of Cancer Research